Implantable glucose sensor with prolonged accuracy

Information

  • Research Project
  • 7692906
  • ApplicationId
    7692906
  • Core Project Number
    R44DK074243
  • Full Project Number
    5R44DK074243-04
  • Serial Number
    74243
  • FOA Number
    PA-07-280
  • Sub Project Id
  • Project Start Date
    6/1/2006 - 18 years ago
  • Project End Date
    8/31/2010 - 13 years ago
  • Program Officer Name
    ARREAZA-RUBIN, GUILLERMO
  • Budget Start Date
    9/1/2009 - 14 years ago
  • Budget End Date
    8/31/2010 - 13 years ago
  • Fiscal Year
    2009
  • Support Year
    4
  • Suffix
  • Award Notice Date
    9/11/2009 - 14 years ago
Organizations

Implantable glucose sensor with prolonged accuracy

DESCRIPTION (provided by applicant): The goal of this study is to fabricate an intravascular glucose sensor that functions accurately for 7 days in vivo. We will utilize a glucose membrane design devised in Phase I to develop a custom outer membrane that has covalently attached bioactive sites to resist biofouling, allows for suitable glucose diffusion, and prevents leaching of potentially toxic by-products. This membrane will be applied to needle-type, amperometric glucose sensor. The versatility of the sensor design will allow easy incorporation into a patient's bloodstream through a central access catheter. The catheter will be designed for 7 day use in the intensive care unit, and will be complete with a hemostatic connector for attaching to an access line, and the electrical connections to an amplifier/display unit. The final prototype will be evaluated for cytotoxicity, hemocompatibilty, and accuracy both using in vitro and in vivo methods. Continuous monitoring of blood glucose levels has been an elusive goal, but would greatly improve the care for critically ill patients in managing insulin therapy. PUBLIC HEALTH RELEVANCE: The goal in this grant is to make an intravascular glucose sensor that measures blood glucose levels continuously for 7 days. By maintaining sensor function, this technology will provide health care professionals with immediate changes in patient health and decrease complications. Currently sudden changes in glucose levels are not detected leading to increased health care costs and increased risks to patients.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    388052
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:388052\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ACCORD BIOMATERIALS, INC.
  • Organization Department
  • Organization DUNS
    622586696
  • Organization City
    ANN ARBOR
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    481038802
  • Organization District
    UNITED STATES